Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

313.91
-0.6500-0.21%
Volume:127.02K
Turnover:40.15M
Market Cap:18.89B
PE:34.08
High:316.74
Open:314.62
Low:313.91
Close:314.56
52wk High:330.75
52wk Low:249.57
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.76
T/O Rate:0.21%
Dividend:4.72
Dividend Rate:1.50%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.56

Loading ...

Abbvie Exec Says Existing Portfolio Provides 'Clear Line of Sight' to Very Strong Growth Well into Next Decade - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Apogee Fits 'Very Nicely' with Its Business Development Approach - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Plans to Start Enrolling Apogee's Zumilokibart This Year, Targets Launch in Early 2030 - Conf Call

THOMSON REUTERS
·
Sep 15

Abbvie Exec Says Tavapadon U.S. Launch Expected to Have 'Slower Burn' Due to Timing of Medicare Reimbursement - Conf Call

THOMSON REUTERS
·
Sep 15

Why One of the Last Eli Lilly Holdouts Just Upgraded the Stock to Buy

Dow Jones
·
Sep 15

Dow's Nearly 300-Point Fall Led by Losses in Johnson & Johnson, Nike Stocks

Dow Jones
·
Sep 15

Covista to invest $150,000 in The Health Collaborative

TIPRANKS
·
Sep 15

Gix Makes Strategic Investment in Ottonomy, a Physical AI, L4 Autonomy and Robotics Technology Company

GlobeNewswire
·
Sep 15

U.S. Stocks on the MOVE-Eli Lilly, Waystar, Sysco

Reuters
·
Sep 15

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Sep 15

Testosterone Scripts for Women Rise, Along with Denials and Delays

Reuters
·
Sep 15

Berenberg Upgrades Eli Lilly and Co. to Buy From Hold, Adjusts Price Target to $1,400 From $1,220

MT Newswires Live
·
Sep 15

Lilly Gains After Berenberg Upgrades to 'buy' on Obesity Pill Momentum

Reuters
·
Sep 15

Eli Lilly : Berenberg Raises to Buy from Hold; Raises Target Price to $1,400 from $1,220

THOMSON REUTERS
·
Sep 15

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

Reuters
·
Sep 15

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS
·
Sep 15

QuantaMatrix Wins Shareholder Backing for Broad Bio-Healthcare Expansion

TIPRANKS
·
Sep 15

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

TIPRANKS
·
Sep 15

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15